1. Home
  2. SUNS vs KLRS Comparison

SUNS vs KLRS Comparison

Compare SUNS & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sunrise Realty Trust Inc.

SUNS

Sunrise Realty Trust Inc.

HOLD

Current Price

$7.87

Market Cap

126.3M

Sector

Real Estate

ML Signal

HOLD

Logo Kalaris Therapeutics Inc.

KLRS

Kalaris Therapeutics Inc.

HOLD

Current Price

$6.41

Market Cap

144.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SUNS
KLRS
Founded
2023
2019
Country
United States
United States
Employees
N/A
20
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
126.3M
144.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SUNS
KLRS
Price
$7.87
$6.41
Analyst Decision
Hold
Strong Buy
Analyst Count
1
4
Target Price
$8.75
$19.00
AVG Volume (30 Days)
116.1K
80.5K
Earning Date
05-14-2026
05-13-2026
Dividend Yield
15.31%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$70.81
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$8.84
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.46
$2.14
52 Week High
$11.78
$11.88

Technical Indicators

Market Signals
Indicator
SUNS
KLRS
Relative Strength Index (RSI) 41.11 45.92
Support Level $7.46 $4.35
Resistance Level $10.27 $7.18
Average True Range (ATR) 0.22 0.64
MACD 0.05 0.17
Stochastic Oscillator 58.73 64.02

Price Performance

Historical Comparison
SUNS
KLRS

About SUNS Sunrise Realty Trust Inc.

Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS and debt-like preferred equity securities across CRE asset classes and investment mix to include high quality multi-family, condominiums, retail, office, hospitality, industrial, mixed use and specialty-use real estate.

About KLRS Kalaris Therapeutics Inc.

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Share on Social Networks: